> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sac-TMT and sonesitatug vedotin hit Phase 3 gastric survival while missing central PFS
- URL: https://chinapharmadesk.com/gastroesophageal-adc-os-pfs-paradox-sactmt-azd0901/
- Published: 2026-11-21T11:20:21.000Z
- Updated: 2026-11-21T11:20:22.000Z
- Description: Merck and Kelun-Biotech's (HKEX: 06990) TROP2 ADC sac-TMT (TroFuse-015, NCT06356311) and AstraZeneca/Keymed's (02162.HK) CLDN18.2 ADC sonesitatug vedotin (NCT06346392) both hit Phase 3 OS while missing BICR-PFS.
- Author: Lin Yi
- Tags: Desk analysis, Oncology & ADC, Pipeline, Regulation

Within 24 hours on November 19 and November 20, 2026, two Chinese-originated antibody-drug conjugates (`ADCs`) advanced at the top of the global late-line gastroesophageal cancer landscape—and exposed the exact same statistical split between overall survival (`OS`) and blinded central progression-free survival (`BICR-PFS`). On November 20, [Merck (NYSE: MRK) and Sichuan Kelun-Biotech Biopharmaceutical (HKEX: 06990) announced](https://www.onclive.com/view/trofuse-015-meets-primary-os-end-point-with-sac-tmt-in-third-line-or-later-gastroesophageal-adenocarcinoma?ref=chinapharmadesk.com) that the global Phase 3 `TroFuse-015` trial ([NCT06356311](https://clinicaltrials.gov/study/NCT06356311?ref=chinapharmadesk.com), `n=473`) of `TROP2`\-directed ADC `sacituzumab tirumotecan` (`sac-TMT` / `MK-2870` / `SKB264`) met its primary endpoint of `OS` in third-line or later (`3L+`) locally advanced unresectable or metastatic gastroesophageal adenocarcinoma (`GEA`), while missing its secondary endpoint of `BICR-PFS`. One day earlier, [AstraZeneca (LSE/NASDAQ: AZN)](https://www.businesswire.com/news/home/20261119701218/en/Sonesitatug-vedotin-granted-Priority-Review-in-the-US-for-2nd-and-later-line-treatment-of-patients-with-CLDN18.2-positive-advanced-gastricGEJ-cancers?ref=chinapharmadesk.com) and originators [Keymed Biosciences (HKEX: 02162)](https://www.keymedbio.com/cn/newsd.html?id=145&type=1&ref=chinapharmadesk.com) and Lepu Biopharma (`HKEX: 02157`) disclosed that the U.S. Food and Drug Administration (`FDA`) accepted and granted **Priority Review** (target `PDUFA` action date in **Q2 2027**) to the Biologics License Application (`BLA`) for `Claudin 18.2` (`CLDN18.2`)-directed ADC `sonesitatug vedotin` (`Sone-Ve` / `AZD0901` / `CMG901`) based on the global Phase 3 `CLARITY-Gastric01` trial ([NCT06346392](https://clinicaltrials.gov/study/NCT06346392?ref=chinapharmadesk.com), `n=594`)—a study that doubled `3L+` median `OS` from **5.0 to 10.0 months** (`HR 0.47, p<0.000001`) and improved intention-to-treat (`ITT`) `2L+` `OS` to **10.6 versus 6.4 months** (`HR 0.58, p=0.000004`), yet narrowly missed its co-primary `ITT` `BICR-PFS` endpoint (**4.2 versus 3.8 months**, `HR 0.77, p=0.053193`).

For global oncology investors and regulatory teams, the twin announcements carry two immediate implications. First, five Chinese-originated `ADCs`—spanning `TROP2`, `CLDN18.2`, and `EGFR×HER3`—now anchor the late-stage global and domestic registration pipeline for pretreated gastric and gastroesophageal junction (`GEJ`) cancer. Second, in direct contrast to [Akeso (HKEX: 09926) and Summit Therapeutics’ (NASDAQ: SMMT) ivonescimab FDA Complete Response Letter](https://chinapharmadesk.com/akeso-summit-ivonescimab-fda-crl/) two weeks ago—where a `PFS` benefit without statistically significant `OS` failed U.S. review—the FDA’s grant of Priority Review to `sonesitatug vedotin` confirms that robust `OS` separation overrides a central `PFS` miss in refractory upper gastrointestinal tumors, even as subgroup hazard ratios (`2L` `OS HR 0.88` versus `3L+` `OS HR 0.47`) set up a critical Q2 2027 U.S. label-scope test.

## Six Chinese-originated and global gastroesophageal ADCs compared

While Astellas Pharma’s (`TSE: 4503`) naked monoclonal antibody `zolbetuximab` (`Vyloy`) established `CLDN18.2` in first-line `HER2`\-negative gastric cancer (requiring ≥ 75% moderate-to-strong `2+/3+` membranous staining), `ADCs` have fractured the pretreated gastroesophageal market across three distinct axes: **target biomarker cutoffs** (`all-comer TROP2` versus `CLDN18.2 >= 25%` at any intensity versus `CLDN18.2 >= 75%` at `2+/3+`), **cytotoxic payload classes** (`topoisomerase I` inhibitors versus microtubule inhibitor `MMAE`), and **commercial rights structures** (full global out-licensing, ex-Greater China splits, or domestic pharma buyouts):

| Asset & Codes                                            | Originator / Global Partner & Deal Structure                                                                                                                                         | Target & Biomarker Cutoff                                                             | Linker & Payload (DAR)                                                                     | Pivotal Trial & Line (NCT ID)                                                                                | Primary Endpoint Readout (OS vs. PFS)                                                                                                                                                       | Regulatory Status (as of Nov 21, 2026)                                                                                                                                                     |
| -------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **sacituzumab tirumotecan (sac-TMT / MK-2870 / SKB264)** | [Kelun-Biotech (06990.HK)](https://chinapharmadesk.com/kelun-liu-sichuan-succession-sactmt-pivot/) / Merck (NYSE: MRK, ex-Greater China exclusive license)                           | **TROP2 (All-comer)**; central tissue testing for stratification, no cutoff exclusion | Pyrimidine-sulfone hydrolyzable linker + belotecan-derivative Topo-I (KL610023, DAR \~7.4) | **TroFuse-015** (NCT06356311, n=473), global 3L+ GEA (4 mg/kg Days 1, 15, 29 Q6W vs. TPC)                    | **Primary OS: Met** across all TROP2 subgroups; **Secondary BICR-PFS: Missed**; nominal ORR improvement                                                                                     | Global regulatory filings planned (Nov 20, 2026); China 3L+ Phase 3 OptiTROP-Gastric01 (NCT06023797) ongoing                                                                               |
| **sonesitatug vedotin (Sone-Ve / AZD0901 / CMG901)**     | Keymed (02162.HK, 70% KYM) & Lepu (02157.HK, 30% KYM) / AstraZeneca (AZN, $63m upfront + $45m Ph3 milestone + up to $1.1b total, global incl. China)                                 | **CLDN18.2 >= 25% of tumor cells at any intensity** (\~60% of GC/GEJ population)      | Protease-cleavable linker + MMAE microtubule payload (DAR \~4)                             | **CLARITY-Gastric01** (NCT06346392, n=594, 19 countries), global 2L+ GEC (2.2 mg/kg Q3W n=267 vs. ICT n=265) | **Co-primary 3L+ OS: Met** (10.0 vs. 5.0 mo, HR 0.47, p<0.000001); **Key secondary ITT OS: Met** (10.6 vs. 6.4 mo, HR 0.58); **Co-primary ITT BICR-PFS: Missed** (4.2 vs. 3.8 mo, p=0.0532) | **U.S. FDA BLA Priority Review** (Nov 19, 2026; PDUFA **Q2 2027**); **China [NMPA (CDE)](https://chinapharmadesk.com/china-pharma-glossary/) NDA accepted** (Oct 8, 2026); EU under review |
| **arcotatug tavatecan (IBI343 / TAK-921)**               | Innovent Biologics (01801.HK) / Takeda (TSE: 4502 / NYSE: TAK, Oct 2025 $1.2b upfront / $11.4b package for ex-Greater China rights)                                                  | **CLDN18.2 >= 75% of tumor cells at 2+/3+ membranous intensity**                      | Cleavable linker + exatecan Topo-I payload (DAR \~4) with Fc-silenced antibody             | **G-HOPE-001** (NCT06238843), multi-regional 3L+ GC/GEJ vs. investigator’s choice                            | **Co-primary PFS: Met** at June 2026 interim analysis; co-primary OS maturing                                                                                                               | **China NMPA NDA accepted under Priority Review** (June 2026); global filings pending mature OS                                                                                            |
| **vetecotatug vedotin (LM-302 / TPX-4589)**              | LaNova Medicines / Sino Biopharmaceutical (01177.HK, acquired via \~$500m net buyout of LaNova in July 2025)                                                                         | **CLDN18.2 positive** (\>= 25% at 2+/3+ in 1L Phase 3 combination)                    | Cleavable valine-citrulline linker + MMAE payload (DAR \~4)                                | **China Phase 3** (NCT05934331), 3L+ GC/GEJ; plus 1L Phase 3 + PD-1 (dosed Apr 2026)                         | **Interim dual endpoints: Met** (June 2026 announcement; numerical effect sizes slated for early 2027 congress)                                                                             | **China NMPA NDA accepted under Priority Review** (June 23, 2026); U.S. FDA Orphan Drug Designation                                                                                        |
| **SHR-A1904**                                            | Jiangsu Hengrui (600276.SS / 01276.HK) (wholly owned)                                                                                                                                | **CLDN18.2 positive** (Phase 1 *Nature Medicine* Sept 2025)                           | Cleavable linker + proprietary Topo-I payload                                              | **China Phase 3** (NCT06649292, estimated n=524), 2L GC/GEJ vs. paclitaxel/docetaxel/irinotecan              | **Single primary endpoint: OS** (recruiting; primary completion target Sept 20, 2027)                                                                                                       | China CDE Breakthrough Therapy Designation (BTD, Dec 26, 2025)                                                                                                                             |
| **iza-bren (BL-B01D1 / izalontamab brengitecan)**        | [Sichuan Biokin / SystImmune (688506.SS) / BMS (NYSE: BMY, $800m upfront + $500m milestones paid)](https://chinapharmadesk.com/biokin-systimmune-bms-izabren-second-250m-milestone/) | **EGFR×HER3 bispecific** (broad epithelial expression in HER2\-negative GC/GEJ)       | Cleavable linker + Ed-04 camptothecin Topo-I payload (DAR \~8)                             | **China Phase 3** (NCT06496516, 2L+ GC/GEJ) & Phase 2 1L HER2- GC/GEJ \+ sintilimab                          | Phase 2 1L HER2- GC/GEJ \+ sintilimab poster at **ESMO Asia (Dec 4, 2026, 17:15 SGT, Prof. He Wei)**                                                                                        | Phase 3 recruiting in 2L+ GC/GEJ; approved/filed in NSCLC and NPC                                                                                                                          |

## Why both Phase 3 trials hit OS while missing central PFS

In solid-tumor oncology, drugs far more commonly achieve progression-free survival (`PFS`) while failing to demonstrate overall survival (`OS`) after post-progression crossover. Seeing two independent global Phase 3 trials—one with a `TROP2` `Topo-I` `ADC` (`TroFuse-015`) and one with a `CLDN18.2` `MMAE` `ADC` (`CLARITY-Gastric01`)—deliver the exact opposite outcome (`OS` positive, `BICR-PFS` negative) points to three structural features of heavily pretreated gastroesophageal carcinoma:

1. **Rapid first-scan progression compresses median `PFS` separation**: In `3L+` gastric and `GEJ` adenocarcinoma, standard single-agent chemotherapy comparators (`trifluridine/tipiracil` `[Lonsurf]`, `irinotecan`, `paclitaxel`, `docetaxel`, or China-specific `apatinib`) typically progress at or near the first scheduled radiographic assessment at Week 6 to Week 12\. In `CLARITY-Gastric01`, median `BICR-PFS` in the `ITT` population was **4.2 months** (`95% CI, 3.5–5.3`) on `sonesitatug vedotin` versus **3.8 months** (`95% CI, 3.0–4.2`) on comparator therapy (`HR 0.77, p=0.053193`). When nearly half of patients progress around the second restaging scan, the median `PFS` point estimate barely moves, whereas the hazard ratio and survival tail capture durable responders—driving a doubling of 12-month `OS` in `3L+` patients from **18.1% to 38.1%** (`median OS 10.0 vs. 5.0 months, HR 0.47`).
2. **High central-versus-local radiographic discordance in peritoneal and gastric wall disease**: Advanced gastric cancer frequently metastasizes to the peritoneum, omentum, and retroperitoneal lymph nodes, accompanied by non-measurable malignant ascites and diffuse primary gastric wall thickening. Blinded central radiologists (`BICR`) reading scans without clinical context frequently call early equivocal fluid changes or non-target lesion shifts differently from treating physicians. In `CLARITY-Gastric01`, while `ITT` `BICR-PFS` missed statistical significance (`4.2 vs. 3.8 months, HR 0.77`), **investigator-assessed `PFS` in the exact same `ITT` population showed a clear 4.4 versus 3.0 month separation (`HR 0.59`, `95% CI, 0.48–0.73`)**, and `3L+` `BICR-PFS` separated at **4.1 versus 2.7 months** (`HR 0.56`, `95% CI, 0.43–0.74`, though not formally tested under the multiplicity hierarchy).
3. **Different trial endpoint hierarchies determined headline success**: Merck designed `TroFuse-015` (`n=473`) exclusively in `3L+` `GEA` with **`OS` as the sole primary endpoint** and `BICR-PFS` relegated to a secondary endpoint—insulating `sac-TMT` from central radiographic noise. Similarly, Jiangsu Hengrui’s ongoing 524-patient Phase 3 trial of `SHR-A1904` in `2L` `CLDN18.2`\-positive `GC/GEJ` (`NCT06649292`) uses `OS` as its single primary endpoint. By contrast, AstraZeneca designed `CLARITY-Gastric01` (`n=594`) across a combined `2L+` population with **dual primary endpoints** (`3L+ OS` and `ITT 2L+ BICR-PFS`), winning the trial on the `3L+ OS` alpha split while missing the `ITT BICR-PFS` gate.

## The Q2 2027 FDA label question for sonesitatug vedotin: 2L+ or 3L+?

Although AstraZeneca’s `BLA` was accepted under Priority Review for the broad `**2L+**` `CLDN18.2 >= 25%` population, the subgroup forest plot presented by Professor Xu Ruihua at the 2026 ESMO Presidential Symposium highlights a sharp regulatory question for the FDA’s Oncology Center of Excellence (`OCE`) ahead of the Q2 2027 `PDUFA` date:

- **Biomarker cutoff breadth is well-supported**: Across expression strata in `CLARITY-Gastric01`, patients with high expression (`CLDN18.2 >= 75%`) achieved a median `OS` of **10.6 versus 6.4 months** (`HR 0.59`, `95% CI, 0.45–0.78`), while those in the lower **`25% to <75%`** bracket achieved **10.5 versus 6.2 months** (`HR 0.63`, `95% CI, 0.42–0.94`). That consistency validates `sonesitatug vedotin`’s `MMAE` bystander effect and supports its lower   **≥ 25%** threshold (covering \~60% of gastric tumors) over the stricter   **≥ 75% at `2+/3+`** cutoff used by Innovent and Takeda’s `arcotatug tavatecan` (`IBI343`) in `G-HOPE-001`.
- **Line-of-therapy and anatomic site heterogeneity is much wider**: While `3L+` patients (`n=178 vs. 177`, \~67% of the `2.2 mg/kg` cohort) delivered an overwhelming `OS` benefit (**10.0 versus 5.0 months**, `HR 0.47`), the unadjusted `OS` hazard ratio among **`2L` patients** was `**HR 0.88**` (`95% CI, 0.60–1.30`)—where active comparator regimens included `ramucirumab + paclitaxel`—and `**HR 1.08**` (`95% CI, 0.68–1.71`) in the gastroesophageal junction and esophageal adenocarcinoma (`GEJ/EAC`) subset.

For `sac-TMT` (`MK-2870`), Merck avoided the `2L` `ramucirumab + paclitaxel` comparator hurdle in `TroFuse-015` by restricting enrollment to `3L+` patients—and gained an all-comer survival readout that requires no companion diagnostic cutoff at all (`OS` benefit consistent regardless of `TROP2` expression). For [Kelun-Biotech (06990.HK), which completed its generational chairmanship transition to Liu Sichuan on November 18](https://chinapharmadesk.com/kelun-liu-sichuan-succession-sactmt-pivot/), `TroFuse-015` represents the second positive global Phase 3 readout under Merck’s 18-trial global `TroFuse` program, expanding `sac-TMT` beyond lung, breast, and gynecologic malignancies into upper gastrointestinal oncology.

## What to watch next

1. **December 4, 2026 (`ESMO Asia`, Singapore)**: SystImmune and Sichuan Biokin (`688506.SS`) will present seven abstracts across `iza-bren` (`BL-B01D1`, including the `1L` `HER2`\-negative `GC/GEJ` \+ `sintilimab` Phase 2 poster at `17:15 SGT`) and `HER2` `ADC` `T-Bren` (`BL-M07D1`, oral presentations in colorectal and urothelial cancers on December 4 and 6).
2. **Early 2027 gastrointestinal oncology congress (`ASCO GI`)**: Expected full numerical presentation of `TroFuse-015` (`median OS`, hazard ratio, Grade ≥ 3 stomatitis and hematologic toxicity rates, and `TROP2`\-high vs. `TROP2`\-low subgroup curves) alongside Sino Biopharm’s (`01177.HK`) Phase 3 readout for `vetecotatug vedotin` (`LM-302`).
3. **Q2 2027 U.S. FDA `PDUFA` decision for `sonesitatug vedotin` (`AZD0901`)**: Whether the FDA grants AstraZeneca the full `2L+` `CLDN18.2 >= 25%` gastric/`GEJ`/`EAC` indication or narrows the U.S. label to `3L+` gastric adenocarcinoma, and whether any approval milestone is triggered for Keymed (`70%` of `KYM`) and Lepu Biopharma (`30%` of `KYM`).